An Expanded Access Study of T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer

Article

Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.

Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.

This analysis was not as stringent as a conventional clinical trial, Yardley says, and aimed to evaluate patients treated with T-DM1 in the community setting. In this trial, patients received a median of 8 prior therapies and were able to receive T-DM1 before its FDA approval.

Clinical Pearls

The time from initial metastatic diagnosis to receiving T-DM1 in this trial was a mean of 42 months, Yardley says, which is astounding and highlights the benefit of HER2-targeted therapies. Among patients who remained on T-DM1 for over a year, median time from diagnosis to T-DM1 was 60 months. This as well reinforces the advancements of HER2-targeted therapies, Yardley says.

  • This trial looked at T-DM1 in the community setting of patients
  • The patient population received a median of 8 prior therapies for HER2+ metastatic disease
  • Safety profile and activity were similar to previous conventional clinical trials
Recent Videos
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Related Content